Antidepressant use increases risk of head injuries among persons with Alzheimer’s disease
Cypralis Limited announces grant award
Researchers find a potential target for anti-Alzheimer treatments
Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia
Alkermes submits NDA to FDA for aripiprazole lauroxil for treatment of schizophrenia
Alkermes initiates FORWARD-5 clinical study of ALKS 5461
Alkermes to present data on new medicines in development for schizophrenia and depression